Ionis Pharmaceuticals (IONS) Q4 Earnings Preview: What You Should Know Beyond the Headline EstimatesZacks Investment Research • 02/15/24
Olezarsen receives Orphan Drug designation from U.S. FDA for familial chylomicronemia syndromePRNewsWire • 02/15/24
Eplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-mediated amyloid cardiomyopathyPRNewsWire • 02/08/24
Vect-Horus Enters Exclusive License Agreement with Ionis Pharmaceuticals to Advance Systemic Delivery of RNA-Targeted Medicines for Neurological DiseasesBusiness Wire • 01/30/24
Ionis announces positive topline results from Phase 3 OASIS-HAE study of investigational donidalorsen in patients with hereditary angioedemaPRNewsWire • 01/22/24
Ionis poised for continued momentum in 2024 with product launches and key advances in robust pipeline of investigational medicines for serious diseasesPRNewsWire • 01/08/24
Ionis Pharmaceuticals, AstraZeneca get FDA approval for rare genetic disease treatmentMarket Watch • 12/22/23
WAINUA™ (eplontersen) granted regulatory approval in the U.S. for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosisPRNewsWire • 12/21/23
Ionis announces European licensing agreement with Otsuka for donidalorsen in hereditary angioedemaPRNewsWire • 12/18/23
Ionis shares positive clinical update from ongoing trial of ION582 for Angelman syndromePRNewsWire • 11/11/23
Ionis presents positive two-year results from the Phase 2 open label extension study of donidalorsen in patients with hereditary angioedemaPRNewsWire • 11/09/23